David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on HLS Therapeutics Inc (HLS – Research Report). The associated price target is C$9.50.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
David Martin PhD’s rating is based on the financial performance and future guidance provided by HLS Therapeutics Inc. The company reported fourth-quarter 2024 revenues that aligned with expectations and slightly exceeded adjusted EBITDA forecasts, indicating strong operational efficiency.
Furthermore, the management’s guidance for 2025 suggests continued growth, with projected total revenues ranging from US$55.7 million to US$57.9 million and adjusted EBITDA between $19.5 million and $20.5 million. These positive financial indicators and the company’s strategic positioning in the specialty pharmaceutical sector contribute to the Buy rating.